Analyst Ratings January 29, 2026

Cantor Fitzgerald Boosts Lam Research Target to $320 After Strong 2025 Results

Firm cites outsized tool revenue growth, raised 2026 EPS estimate and bullish WFE outlook as analysts lift targets across the board

By Sofia Navarro LRCX
Cantor Fitzgerald Boosts Lam Research Target to $320 After Strong 2025 Results
LRCX

Cantor Fitzgerald raised its price objective on Lam Research to $320 while retaining an Overweight rating, citing the company's robust calendar year 2025 results, above-consensus guidance for the March quarter, and a positive wafer fabrication equipment outlook for 2026. Other major brokerages have also moved higher on Lam following earnings and guidance, reflecting broadening analyst confidence.

Key Points

  • Cantor Fitzgerald raised its price target on Lam Research to $320 and maintained an Overweight rating.
  • Lam’s tool revenue grew 40% in calendar year 2025 versus 10% WFE industry growth; March-quarter guidance exceeded consensus at $5.7 billion in revenue and $1.35 EPS.
  • Analysts broadly lifted targets and outlooks, reflecting confidence in WFE spending for 2026 and Lam’s strength in deposition and etch technologies - impacting semiconductor equipment and AI infrastructure-related markets.

Cantor Fitzgerald has increased its price target for Lam Research (NASDAQ:LRCX) to $320.00 and kept an Overweight rating on the semiconductor equipment maker. The firm pointed to a strong calendar year 2025 performance and a favorable outlook for wafer fabrication equipment (WFE) spending as the basis for its revision.

In Cantor Fitzgerald's view, Lam delivered notably stronger tool revenue growth in 2025 than the wider WFE industry. Tool revenue rose 40% for Lam in calendar year 2025, compared with WFE industry growth of 10% over the same period. The firm also noted that Lam's guidance for the March quarter came in ahead of consensus: the company projected $5.7 billion in revenue and $1.35 in earnings per share, versus consensus estimates of $5.3 billion and $1.19.

Looking further out, Cantor Fitzgerald emphasized a robust WFE outlook for 2026, forecasting 23% growth to $135 billion, which the research house said is consistent with its own modeling. Lam has reported that equipment demand remains tight and that visibility into 2027 is strong, with 2027 expected to be another year of growth.

The research note also discussed market share trends. Lam reported gaining more than 100 basis points of WFE market share during 2025. Cantor Fitzgerald's analysis suggests the gains may be larger - closer to 250 basis points - a difference the firm attributed to Lam's leadership in deposition and etch technologies across key end-markets including advanced foundry, NAND, DRAM, and advanced packaging.

On earnings, Cantor Fitzgerald increased its calendar year 2026 earnings-per-share estimate for Lam to $6.10, versus consensus of $5.40. The firm identified a potential "stretch goal" of $7.00. For 2027, Cantor Fitzgerald continued to model $10 in earnings per share, a figure the firm said could be "potentially conservative" given the early stage of AI infrastructure development.


Other brokerages have also adjusted their targets after Lam's recent results and guidance. JPMorgan raised its price target to $300 from $165, citing factors such as increased customer expedite requests and the company’s operational effectiveness. TD Cowen lifted its target to $290 from $170, pointing to an optimistic WFE outlook for 2026. Berenberg raised its target to $265 following positive guidance on WFE spending trends. Bernstein increased its price target to $275. KeyBanc Capital Markets reviewed the company’s second-quarter earnings results and maintained its Sector Weight rating.

Together, these moves illustrate a growing level of analyst confidence in Lam Research’s near-term demand trajectory and its competitive position in deposition and etch platforms. Cantor Fitzgerald’s combination of higher near-term earnings estimates and an increased price target underscores the firm's view that the company is well positioned within a tight equipment demand environment and a multi-year growth backdrop for WFE.


Context and implications

While the research notes and revised targets vary in magnitude, the common thread among the analysts cited is a more favorable read on customer demand patterns, the company's operational responsiveness, and the broader WFE cycle. Cantor Fitzgerald’s forecasted 23% expansion of WFE spending in 2026 to $135 billion, and its view that equipment demand remains constrained with visibility into 2027, are central to its more bullish stance on Lam.

Investors and industry observers will likely monitor incoming order flow, management commentary on customer timelines and expedite activity, and any additional color on market share shifts in deposition and etch to assess the sustainability of the revisions presented by Cantor Fitzgerald and other brokers.

Risks

  • Variation in market-share measurement - company-reported gains of more than 100 basis points in 2025 contrast with Cantor Fitzgerald’s estimate of closer to 250 basis points, creating uncertainty about the exact magnitude of share gains - this affects competitive dynamics within the semiconductor equipment sector.
  • Long-term forecasts tied to AI infrastructure remain uncertain - Cantor Fitzgerald notes its $10 per-share target for 2027 could be "potentially conservative" given the early stage of AI infrastructure development, indicating uncertainty in modeling AI-driven demand.
  • Analyst opinions are not unanimous - while multiple firms raised targets, KeyBanc maintained a Sector Weight rating after reviewing second-quarter results, reflecting differing interpretations of the company’s near-term outlook and the WFE cycle.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026